شنبه 2 اسفند 1404
[Archive]
دوره 33، شماره 161 - ( 9-1404 )
جلد 33 شماره 161 صفحات 272-261 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hajjari S N, Daneshafrooz N. Beta-Secretase 1 and gamma-Secretase Activating Protein-Related MicroRNAs in Alzheimer's Disease: A Narrative Review. J Adv Med Biomed Res 2025; 33 (161) :261-272
URL: http://journal.zums.ac.ir/article-1-7719-fa.html
URL: http://journal.zums.ac.ir/article-1-7719-fa.html
Beta-Secretase 1 and gamma-Secretase Activating Protein-Related MicroRNAs in Alzheimer's Disease: A Narrative Review. Journal of Advances in Medical and Biomedical Research. 1404; 33 (161) :261-272
چکیده: (549 مشاهده)
Alzheimer's Disease (AD) represents an advancing neurodegenerative condition, and early diagnostic biomarkers are crucial to detect it in the pre-dementia stage. The formation of Amyloid beta relies on the proteolytic processing of precursor proteins, a critical biological stage controlled by the enzymes Beta-Secretase 1 (BACE1) and gamma-Secretase activating protein (GSAP). Multiple factors regulate the expression of BACE1 and GSAP, with microRNAs (miRs) playing a particularly significant role. Notably, fluctuations in the expression of certain miRs can precede any detectable changes in AD-associated genes. This is probably related to the unique and dynamically regulated expression pattern of specific miRs, such as members of the miR-29 family, miR-124, and miR-455-3p, which have shown significant regulatory roles in the pathophysiological context of AD. Thus, miRs may serve as non-invasive, cost-effective biomarkers for AD screening and diagnosis. For this purpose, a thorough literature search was conducted across the PubMed, Scopus, and Web of Science databases to find original English-language articles published between 2008 and 2025. The search focused on studies examining miRs that target BACE1 or GSAP in the context of Alzheimer's amyloidogenic pathways. Study selection was performed according to narrative review principles. Therefore, this review aims to pinpoint the specific microRNAs that modulate BACE1 and GSAP and to assess their clinical utility as new biomarkers for early-stage AD detection.
نوع مطالعه: مقاله مروری |
موضوع مقاله:
Medical Biology
دریافت: 1404/4/4 | پذیرش: 1404/9/10 | انتشار: 1404/9/21
دریافت: 1404/4/4 | پذیرش: 1404/9/10 | انتشار: 1404/9/21
فهرست منابع
1. Cole SL, Vassar R. The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener. 2007;2:22. [DOI:10.1186/1750-1326-2-22] [PMID] [PMCID]
2. Jin C, Wang J, Wang Y, Jia B, Guo X, Yang G, et al. Modulation of amyloid precursor protein cleavage by γ-secretase activating protein through phase separation. Proc Natl Acad Sci U S A. 2022;119(12):e2122292119. [DOI:10.1073/pnas.2122292119] [PMID] [PMCID]
3. Schonrock N, Matamales M, Ittner LM, Götz J. MicroRNA networks surrounding APP and amyloid-β metabolism--implications for Alzheimer's disease. Exp Neurol. 2012;235(2):447-54. [DOI:10.1016/j.expneurol.2011.11.013] [PMID]
4. Femminella GD, Ferrara N, Rengo G. The emerging role of microRNAs in Alzheimer's disease. Front Physiol. 2015;6:40. [DOI:10.3389/fphys.2015.00040] [PMID] [PMCID]
5. Brand AL, Lawler PE, Bollinger JG, Li Y, Schindler SE, Li M, et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review. Alzheimers Res Ther. 2022;14(1):195. [DOI:10.1186/s13195-022-01117-1] [PMID] [PMCID]
6. Angira D, Chikhale R, Mehta K, Bryce RA, Thiruvenkatam V. Tracing the GSAP-APP C-99 Interaction Site in the β-Amyloid Pathway Leading to Alzheimer's Disease. ACS Chem Neurosci. 2019;10(8):3868-79. [DOI:10.1021/acschemneuro.9b00332] [PMID]
7. Vassar R, Kandalepas PC. The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease. Alzheimers Res Ther. 2011;3(3):20. [DOI:10.1186/alzrt82] [PMID] [PMCID]
8. Xu P, Chang JC, Zhou X, Wang W, Bamkole M, Wong E, et al. GSAP regulates lipid homeostasis and mitochondrial function associated with Alzheimer's disease. J Exp Med. 2021;218(8):e20202446. [DOI:10.1084/jem.20202446] [PMID] [PMCID]
9. Berti V, Polito C, Lombardi G, Ferrari C, Sorbi S, Pupi A. Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. Neurol Sci. 2016;37(5):663-72. [DOI:10.1007/s10072-016-2477-1] [PMID]
10. Geekiyanage H, Jicha GA, Nelson PT, Chan C. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp Neurol. 2012;235(2):491-6. [DOI:10.1016/j.expneurol.2011.11.026] [PMID] [PMCID]
11. During EH, Osorio RS, Elahi FM, Mosconi L, de Leon MJ. The concept of FDG-PET endophenotype in Alzheimer's disease. Neurol Sci. 2011;32(4):559-69. [DOI:10.1007/s10072-011-0633-1] [PMID] [PMCID]
12. Toledo JB, Shaw LM, Trojanowski JQ. Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. Alzheimers Res Ther. 2013;5(2):1-10. [DOI:10.1186/alzrt162] [PMID] [PMCID]
13. Vassar R, Kovacs DM, Yan R, Wong PC. The β-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. Neurosci J. 2009;29(41):12787-94. [DOI:10.1523/JNEUROSCI.3657-09.2009] [PMID] [PMCID]
14. Jin XF, Wu N, Wang L, Li J. Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol. 2013;33(5):601-13. [DOI:10.1007/s10571-013-9940-9] [PMID] [PMCID]
15. Liu CG, Wang JL, Li L, Wang PC. MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease. Int J Mol Med. 2014;34(1):160-6. [DOI:10.3892/ijmm.2014.1780] [PMID] [PMCID]
16. Chorley BN, Atabakhsh E, Doran G, Gautier JC, Ellinger-Ziegelbauer H, Jackson D, et al. Methodological considerations for measuring biofluid-based microRNA biomarkers. Crit Rev Toxicol. 2021;51(3):264-82. [DOI:10.1080/10408444.2021.1907530] [PMID] [PMCID]
17. Hajjari SN, Mehdizadeh M, Sadigh-Eteghad S, Shanehbandi D, Teimourian S, Baradaran B. Secretases-related miRNAs in Alzheimer's disease: new approach for biomarker discovery. Neurol Sci. 2017;38(11):1921-6. [DOI:10.1007/s10072-017-3086-3] [PMID]
18. Grande G, Valletta M, Rizzuto D, Xia X, Qiu C, Orsini N, et al. Blood-based biomarkers of Alzheimer's disease and incident dementia in the community. Nature Medicine. 2025;31:2027-35. [DOI:10.1038/s41591-025-03605-x] [PMID] [PMCID]
19. Pirrò S, Matic I, Colizzi V, Galgani A. The microRNA analysis portal is a next-generation tool for exploring and analyzing miRNA-focused data in the literature. Sci Rep. 2021;11(1):9007. [DOI:10.1038/s41598-021-88617-6] [PMID] [PMCID]
20. Bogdanovic N. The challenges of diagnosis in alzheimer's disease. Eur Neurol Rev. 2018;14:15-6. [DOI:10.17925/USN.2018.14.1.15]
21. Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, et al. Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement. 2014;10(1):109-14. [DOI:10.1016/j.jalz.2013.10.007] [PMID] [PMCID]
22. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595-608. [DOI:10.15252/emmm.201606210] [PMID] [PMCID]
23. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F. Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol. 2012;69(7):824-31. [DOI:10.1001/archneurol.2011.1841] [PMID] [PMCID]
24. Shen Y, Wang H, Sun Q, Yao H, Keegan AP, Mullan M, et al. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. Biol Psychiatry. 2018;83(5):447-55. [DOI:10.1016/j.biopsych.2017.02.007] [PMID] [PMCID]
25. Pan X, Green BD. Temporal Effects of Neuron-specific beta-secretase 1 (BACE1) Knock-in on the Mouse Brain Metabolome: Implications for Alzheimer's Disease. Neuroscience. 2019;397:138-46. [DOI:10.1016/j.neuroscience.2018.11.031] [PMID]
26. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488(7409):96-9. [DOI:10.1038/nature11283] [PMID] [PMCID]
27. Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord. 2013;6(1):19-33. [DOI:10.1177/1756285612461679] [PMID] [PMCID]
28. Vakilian A, Masoumi J, Mirzaee S, Khorramdelazad H. Expression analysis of beta-secretase 1 (BACE1) enzyme in peripheral blood of patients with Alzheimer's disease. Caspian J Intern Med. 2019;10(3):276-80.
29. Hébert SS, Horré K, Nicolaï L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A. 2008;105(17):6415-20. [DOI:10.1073/pnas.0710263105] [PMID] [PMCID]
30. Boissonneault V, Plante I, Rivest S, Provost P. MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. J Biol Chem. 2009;284(4):1971-81. [DOI:10.1074/jbc.M807530200] [PMID] [PMCID]
31. Faghihi MA, Zhang M, Huang J, Modarresi F, Van der Brug MP, Nalls MA, et al. Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol. 2010;11(5):R56. [DOI:10.1186/gb-2010-11-5-r56] [PMID] [PMCID]
32. Ding Y, Tian M, Liu J, Deng Y, Li W, Feng X, et al. Expression profile of miRNAs in APP swe/PSΔE9 transgenic mice. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32(9):1280-3.
33. Fang M, Wang J, Zhang X, Geng Y, Hu Z, Rudd JA, et al. The miR-124 regulates the expression of BACE1/β-secretase correlated with cell death in Alzheimer's disease. Toxicol Lett. 2012;209(1):94-105. [DOI:10.1016/j.toxlet.2011.11.032] [PMID]
34. Liu CG, Wang JL, Li L, Xue LX, Zhang YQ, Wang PC. MicroRNA-135a and -200b, potential Biomarkers for Alzheimer׳s disease, regulate β secretase and amyloid precursor protein. Brain Res. 2014;1583:55-64. [DOI:10.1016/j.brainres.2014.04.026] [PMID] [PMCID]
35. Kim J, Yoon H, Chung DE, Brown JL, Belmonte KC, Kim J. miR-186 is decreased in aged brain and suppresses BACE1 expression. J Neurochem. 2016;137(3):436-45. [DOI:10.1111/jnc.13507] [PMID] [PMCID]
36. Müller M, Jäkel L, Bruinsma IB, Claassen JA, Kuiperij HB, Verbeek MM. MicroRNA-29a Is a Candidate Biomarker for Alzheimer's Disease in Cell-Free Cerebrospinal Fluid. Mol Neurobiol. 2016;53(5):2894-9. [DOI:10.1007/s12035-015-9156-8] [PMID] [PMCID]
37. An F, Gong G, Wang Y, Bian M, Yu L, Wei C. MiR-124 acts as a target for Alzheimer's disease by regulating BACE1. Oncotarget. 2017;8(69):114065-71. [DOI:10.18632/oncotarget.23119] [PMID] [PMCID]
38. Kumar S, Vijayan M, Reddy PH. MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer's disease. Hum Mol Genet. 2017;26(19):3808-22. [DOI:10.1093/hmg/ddx267] [PMID] [PMCID]
39. Xie H, Zhao Y, Zhou Y, Liu L, Liu Y, Wang D, et al. MiR-9 Regulates the Expression of BACE1 in Dementia Induced by Chronic Brain Hypoperfusion in Rats. Cell Physiol Biochem. 2017;42(3):1213-26. [DOI:10.1159/000478919] [PMID]
40. Gong G, An F, Wang Y, Bian M, Yu LJ, Wei C. miR-15b represses BACE1 expression in sporadic Alzheimer's disease. Oncotarget. 2017;8(53):91551-7. [DOI:10.18632/oncotarget.21177] [PMID] [PMCID]
41. Ross SP, Baker KE, Fisher A, Hoff L, Pak ES, Murashov AK. miRNA-431 Prevents Amyloid-β-Induced Synapse Loss in Neuronal Cell Culture Model of Alzheimer's Disease by Silencing Kremen1. Front Cell Neurosci. 2018;12:87. [DOI:10.3389/fncel.2018.00087] [PMID] [PMCID]
42. Yang Q, Zhao Q, Yin Y. miR-133b is a potential diagnostic biomarker for Alzheimer's disease and has a neuroprotective role. Exp Ther Med. 2019;18(4):2711-8. [DOI:10.3892/etm.2019.7855] [PMID] [PMCID]
43. Ansari A, Maffioletti E, Milanesi E, Marizzoni M, Frisoni GB, Blin O, et al. miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease. Neurobiol Aging. 2019;82:102-9. [DOI:10.1016/j.neurobiolaging.2019.06.005] [PMID] [PMCID]
44. Ji Y, Wang D, Zhang B, Lu H. MiR-361-3p inhibits β-amyloid accumulation and attenuates cognitive deficits through targeting BACE1 in Alzheimer's disease. J Integr Neurosci. 2019;18(3):285-91. [DOI:10.31083/j.jin.2019.03.1136] [PMID]
45. Chopra N, Wang R, Maloney B, Nho K, Beck JS, Pourshafie N, et al. MicroRNA-298 reduces levels of human amyloid-β precursor protein (APP), β-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties. Mol Psychiatry. 2021;26(10):5636-57. [DOI:10.1038/s41380-019-0610-2] [PMID] [PMCID]
46. Li J, Wang H. miR-15b reduces amyloid-β accumulation in SH-SY5Y cell line through targetting NF-κB signaling and BACE1. Biosci Rep. 2018;38(6):BSR20180051. [DOI:10.1042/BSR20180051] [PMID] [PMCID]
47. Hajjari SN, Sadigh-Eteghad S, Shanehbandi D, Teimourian S, Shahbazi A, Mehdizadeh M. MicroRNA-4422-5p as a Negative Regulator of Amyloidogenic Secretases: A Potential Biomarker for Alzheimer's Disease. Neuroscience. 2021;463:108-15. [DOI:10.1016/j.neuroscience.2021.03.028] [PMID]
48. Jash K, Gondaliya P, Sunkaria A, Kalia K. MicroRNA-29b Modulates β-Secretase Activity in SH-SY5Y Cell Line and Diabetic Mouse Brain. Cell Mol Neurobiol. 2020;40(8):1367-81. [DOI:10.1007/s10571-020-00823-4] [PMID] [PMCID]
49. Cao Y, Tan X, Lu Q, Huang K, Tang X, He Z. MiR-29c-3p May Promote the Progression of Alzheimer's Disease through BACE1. J Healthc Eng. 2021;2021:2031407. [DOI:10.1155/2021/2031407] [PMID] [PMCID]
50. Du W, Lei C, Dong Y. MicroRNA-149 is downregulated in Alzheimer's disease and inhibits β-amyloid accumulation and ameliorates neuronal viability through targeting BACE1. Genet Mol Biol. 2021;44(1):e20200064. [DOI:10.1590/1678-4685-gmb-2020-0064] [PMID] [PMCID]
51. Wang X, Li M, Hu Y. miR-29c-3p Attenuates beta-Amyloid-Induced Neurotoxicity in Alzheimer's Disease Through Regulating beta-Site Amyloid Precursor Protein-Cleaving Enzyme 1. Physiol Res. 2023;72(6):833-41. [DOI:10.33549/physiolres.935084] [PMID] [PMCID]
52. Rasadi A, Talesh Sasani S, Ajamian F. Elevated BACE1 mRNA Level is Associated with Lower miR-15a-5p and miR-19b-3p Expressions in Peripheral Blood Mononuclear Cells of Patients with Late-Onset Alzheimer's Disease: Wet Lab Results and Bioinformatics Analysis. Mol Neurobiol. 2025;62(10):13722-35. [DOI:10.1007/s12035-025-05159-y] [PMID]
53. Deng Y, Ding Y, Hou D. Research status of the regulation of miRNA on BACE1. Int J Neurosci. 2014;124(7):474-7. [DOI:10.3109/00207454.2013.858249] [PMID]
54. Kiko T, Nakagawa K, Tsuduki T, Furukawa K, Arai H, Miyazawa T. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer's disease. J Alzheimers Dis. 2014;39(2):253-9. [DOI:10.3233/JAD-130932] [PMID]
55. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis. 2008;14(1):27-41. [DOI:10.3233/JAD-2008-14103] [PMID]
56. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101-12. [DOI:10.1038/nrm2101] [PMID] [PMCID]
57. He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature. 2010;467(7311):95-8. [DOI:10.1038/nature09325] [PMID] [PMCID]
58. Satoh J, Tabunoki H, Ishida T, Saito Y, Arima K. Immunohistochemical characterization of γ-secretase activating protein expression in Alzheimer's disease brains. Neuropathol Appl Neurobiol. 2012;38(2):132-41. [DOI:10.1111/j.1365-2990.2011.01206.x] [PMID]
59. Wong E, Liao GP, Chang JC, Xu P, Li YM, Greengard P. GSAP modulates γ-secretase specificity by inducing conformational change in PS1. Proc Natl Acad Sci U S A. 2019;116(13):6385-90. [DOI:10.1073/pnas.1820160116] [PMID] [PMCID]
60. Hussain I, Fabrègue J, Anderes L, Ousson S, Borlat F, Eligert V, et al. The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation. J Biol Chem. 2013;288(4):2521-31. [DOI:10.1074/jbc.M112.370924] [PMID] [PMCID]
61. Perez SE, Nadeem M, Malek-Ahmadi MH, He B, Mufson EJ. Frontal Cortex and Hippocampal γ-Secretase Activating Protein Levels in Prodromal Alzheimer Disease. Neurodegener Dis. 2017;17(6):235-41. [DOI:10.1159/000477937] [PMID] [PMCID]
62. Chu J, Wisniewski T, Praticò D. GATA1-mediated transcriptional regulation of the γ-secretase activating protein increases Aβ formation in Down syndrome. Ann Neurol. 2016;79(1):138-43. [DOI:10.1002/ana.24540] [PMID] [PMCID]
63. Hajjri SN, Sadigh-Eteghad S, Mehrpour M, Moradi F, Shanehbandi D, Mehdizadeh M. Beta-Amyloid-Dependent miRNAs as Circulating Biomarkers in Alzheimer's Disease: a Preliminary Report. J Mol Neurosci. 2020;70(6):871-7. [DOI:10.1007/s12031-020-01511-0] [PMID] [PMCID]
64. Liu S, Fan M, Zheng Q, Hao S, Yang L, Xia Q, et al. MicroRNAs in Alzheimer's disease: Potential diagnostic markers and therapeutic targets. Biomed Pharmacother. 2022;148:112681. [DOI:10.1016/j.biopha.2022.112681] [PMID]
65. Alhenaky A, Alhazmi S, Alamri SH, Alkhatabi HA, Alharthi A, Alsaleem MA, et al. Exosomal MicroRNAs in Alzheimer's Disease: Unveiling Their Role and Pioneering Tools for Diagnosis and Treatment. J Clin Med. 2024;13(22):6960. [DOI:10.3390/jcm13226960] [PMID] [PMCID]
66. Fattahi F, Asadi MR, Abed S, Kouchakali G, Kazemi M, Mansoori Derakhshan S, et al. Blood-based microRNAs as the potential biomarkers for Alzheimer's disease: evidence from a systematic review. Metab Brain Dis. 2024;40(1):44. [DOI:10.1007/s11011-024-01431-7] [PMID]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
